These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
169 related items for PubMed ID: 38895121
1. Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome. Yamaguchi K, Tang Q, Poland P, Reay DP, Gregory A, Aggarwal R, Oddis CV, Ascherman DP. Front Immunol; 2024; 15():1399451. PubMed ID: 38895121 [Abstract] [Full Text] [Related]
7. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Kryštůfková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J, Lundberg IE. Arthritis Res Ther; 2014 Oct 10; 16(5):454. PubMed ID: 25301447 [Abstract] [Full Text] [Related]
8. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, Spain. Menor Almagro R, Jurado Roger A, Rodríguez Gutiérrez FJ, Solís Díaz R, Cardiel MH, Salaberri Maestrojuan JJ. Reumatol Clin; 2016 Oct 10; 12(5):256-62. PubMed ID: 26725021 [Abstract] [Full Text] [Related]
9. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, Levesque H, Jouen F. Semin Arthritis Rheum; 2012 Jun 10; 41(6):890-9. PubMed ID: 22078416 [Abstract] [Full Text] [Related]
10. Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation. Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V, PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium. Arthritis Rheumatol; 2024 May 10; 76(5):751-762. PubMed ID: 38130019 [Abstract] [Full Text] [Related]
17. Spreading of the immune response from 52 kDaRo and 60 kDaRo to calreticulin in experimental autoimmunity. Kinoshita G, Keech CL, Sontheimer RD, Purcell A, McCluskey J, Gordon TP. Lupus; 1998 May 10; 7(1):7-11. PubMed ID: 9493142 [Abstract] [Full Text] [Related]
18. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, Furuya MY, Matsuoka N, Kobayashi H, Watanabe H, Koga T, Shimizu T, Kawakami A, Migita K. Medicine (Baltimore); 2019 May 10; 98(20):e15578. PubMed ID: 31096460 [Abstract] [Full Text] [Related]
19. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Intern Med J; 2011 Sep 10; 41(9):674-9. PubMed ID: 20059602 [Abstract] [Full Text] [Related]